Keyword: products

Egis' medicines won the Innovation Grand Prize

Two of Egis’ fixed-dose combination drugs have won the Innovation Grand Prize. The awarded Egis medicines feature significant innovations as they reduce the risk of cardiovascular events related to atherosclerosis due to the combined lipid-lowering therapy. In respect of these two products the company obtained three patents related to active ingredient development and two patents related to formulation development that are all relevant to large-scale manufacturing technologies. The recognition was not without a history, as this is the tenth time an Egis medicine has received an Innovation Prize or Grand Prize.

More

Egis as a special partner at one of the biggest professional events of the year for pharmacists

Once again, Egis was a Gold Exhibitor at the grandExpo, an event with more than two thousand invitees.

More

A Decade-Long Commitment to the Treatment of Cancer

We have commemorated World Cancer Day.

More

The continuous operation of Egis is vital

The quality of life of millions depends on the availability of our medicines, as Egis sells the most boxes of medicine in Hungary. Hungarian doctors most often choose Egis medicines particularly for the therapy of cardiovascular diseases, which is a common disease. Our medicines provide therapeutic solutions for the diseases cardiovascular diseases (38%), for the illnesses of the central nervous system (17%) and respiratory system (10%), further 10% are cancer treatment and immunotherapeutic drugs. Taking these medicines continuously is essential for maintaining the patients’ quality of life and for the success of the therapy.

More

New Unit Inaugurated at Egis’s Körmend Plant

Egis and our consortia partners have won 2,332 billion HUF direct grant in the framework of the innovation tender GINOP-2.2.1-15-2016-00023 for the realisation of the above-mentioned project.

More

Egis Strengthens European Presence in the Biosimilar Area

Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.

More

Egis strengthens presence in Russia by OTC acquisition

Hungarian-based Egis Pharmaceuticals acquired D-Panthenol and women’s health product portfolio from Jadran-Galenski Laboratorij’s (JGL). The company intends to further strengthen its position in major export markets, via select acquisitions.

More
WarningYour browser is out of date. Please, use an updated version! Chrome || Firefox